logo

For the Inventor, By the Inventor

Pine Brook, NJ, United States of America

Raeann Wu

USPTO Granted Patents = 12 


 

Average Co-Inventor Count = 7.6

ph-index = 7

Forward Citations = 94(Granted Patents)


Location History:

  • Pine Brook, NJ (US) (2011 - 2015)
  • East Hanover, NJ (US) (2016 - 2019)

Company Filing History:

goldMedal12 out of 3,923 
 
Novartis Ag
 patents
silverMedal2 out of 8 
 
Novartis Pharma Gmbh
 patents
where one patent can have more than one assignee

Years Active: 2011-2019

Loading Chart...
Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents
1. 10421755 - Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors (2019-09-24),
2. 9802931 - Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors (2017-10-31),
3. 9365565 - Salts of aza-bicyclic di-aryl ethers and pharmaceuticals thereof (2016-06-14),
4. 9163005 - Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide (2015-10-20),
5. 9067896 - Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl) -phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof (2015-06-30),
6. 8829015 - Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide (2014-09-09),
7. 8580806 - Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide (2013-11-12),
8. 8415363 - Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide (2013-04-09),
9. 8389537 - Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide (2013-03-05),
10. 8343984 - Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide (2013-01-01),
11. 8163904 - Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide (2012-04-24),
12. 8063043 - Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide (2011-11-22),

Title: Raeann Wu: Innovating Medicinal Chemistry with Aza-Bicyclic Di-Aryl Ether Salts

Introduction:

In the realm of medicinal chemistry, the work of innovators like Raeann Wu has the potential to revolutionize the field. Hailing from Pine Brook, NJ, Raeann Wu is a prolific inventor and researcher known for his groundbreaking work in the development of aza-bicyclic di-aryl ether salts. Through his patents and collaborations, Wu has made significant contributions to the pharmaceutical industry. Let us delve into his latest patents, career highlights, and noteworthy collaborations.

Latest Patents:

Raeann Wu's most recent patents revolve around salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane. These salts, and methods for synthesizing their precursors, have garnered considerable attention due to their potential applications as medicaments. These inventions pave the way for the development of novel pharmaceutical compositions, adding to the arsenal of medical treatments available.

Career Highlights:

Throughout his career, Raeann Wu has established himself as a prominent figure in the pharmaceutical industry. Having accumulated a total of 12 patents, Wu's expertise spans various areas of medicinal chemistry, with a particular focus on innovative drug design and synthesis. His significant contributions have been recognized both within his company and in the wider scientific community, positioning him as a respected authority in his field.

Collaborations:

At Novartis, Raeann Wu has had the opportunity to collaborate with esteemed researchers and scientists. Notable among his coworkers are Paul William Manley and Wen-Chung Shieh. Collaboration is a cornerstone of scientific progress, allowing for the exchange of ideas, expertise, and resources. Wu's synergistic partnerships have enhanced the impact of his work and further accelerated innovation in the domain of medicinal chemistry.

Conclusion:

Raeann Wu's relentless pursuit of breakthroughs in medicinal chemistry has resulted in a remarkable portfolio of patents and significant contributions to the pharmaceutical industry. His pioneering work with aza-bicyclic di-aryl ether salts showcases his ability to drive innovation and create novel solutions to address medical needs. Through collaborations with fellow researchers, Wu has demonstrated the power of collective knowledge in advancing scientific discovery. As the field continues to evolve, Wu's contributions serve as a testament to the important role inventors and innovators play in shaping the future of medicine and healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…